Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.

被引：0
|
作者：
Zasadny, KR
Rommelfanger, SG
Regan, DD
McCullough, NT
Kroll, S
Stagg, R
Kaminski, MS
Wahl, RL
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Coulter Pharmaceut Inc, S San Francisco, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
114
引用
收藏
页码：29P / 30P
页数：2
相关论文
共 50 条
  • [21] Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia.
    Goldsmith, SJ
    Kostakoglu, L
    Wahl, R
    Alavi, A
    Divgi, C
    Hankins, J
    Zelenetz, A
    Kaminski, M
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 33P - 34P
  • [22] A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    Press, OW
    Unger, JM
    Braziel, RM
    Maloney, DG
    Miller, TP
    LeBlanc, M
    Gaynor, ER
    Rivkin, SE
    Fisher, RI
    BLOOD, 2003, 102 (05) : 1606 - 1612
  • [23] Clinical experience of Weill Cornell Medical Center with 131I-tositumomab (Bexxar™) radioimmunotherapy in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Vallabhajosula, S
    Kroll, S
    Fiore, JM
    Scarano, D
    Hack, S
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 312P - 312P
  • [24] Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Dosik, AD
    Coleman, M
    Kostakoglu, L
    Furman, RR
    Fiore, JM
    Muss, D
    Niesvizky, R
    Shore, T
    Schuster, MW
    Stewart, P
    Vallabhajosula, S
    Goldsmith, SJ
    Leonard, JP
    CANCER, 2006, 106 (03) : 616 - 622
  • [25] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Kaminski, MS
    Radford, JA
    Gregory, SA
    Leonard, JP
    Knox, SJ
    Kroll, S
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7985 - 7993
  • [26] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [27] Re-treatment with Tositumomab and Iodine I131 Tositumomab (the BEXXAR® therapeutic regimen) in patients with non-Hodgkin's lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen.
    Kaminski, MS
    Knox, SJ
    Radford, J
    Gregory, SA
    Leonard, JP
    BLOOD, 2003, 102 (11) : 407A - 407A
  • [28] Bexxar - Tositumomab and iodine I 131 tositumoma - Glaxosmithkline/Corixa - New treatment for non-Hodgkin's lymphoma
    不详
    FORMULARY, 2003, 38 (08) : 455 - 456
  • [29] Iodine I 131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma (NHL): Overall clinical trial experience.
    Zelenetz, AD
    Vose, JM
    Knox, S
    Magnuson, DE
    Kroll, S
    Tidmarsh, G
    Kaminski, MS
    BLOOD, 1999, 94 (10) : 632A - 632A
  • [30] Preliminary results of a multicenter dosimetry, efficacy and safety study with iodine-131 tositumomab in treatment of non-Hodgkin's lymphoma (NHL)
    Kostakoglu, L
    Goldsmith, SJ
    Buchegger, F
    Lewington, V
    Leonard, JP
    Illidge, T
    Ketterer, N
    Kovacsovics, T
    Valente, N
    Bischof-Delaloye, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 979 - 979
12345